Thursday, July 2, 2015
The Sanford Consortium for Regenerative Medicine in La Jolla, Calif., and Takeda Pharmaceutical have agreed to establish a $10 million, five-year innovation alliance that would advance each organization’s research missions. Specifically, translational research and proof-of-concepts research projects will be identified and generated with an ultimate goal of delivering innovative therapeutic products to patients.
Following the completion of the management buyout of Synexus, the new board confirms its intention to expand the footprint of the company through organic growth and acquisition. Synexus, a multi-national company dedicated to the recruitment and running of clinical trials at its own research centers across the globe, intends to become a major player in the U.S., continue to expand its existing network of sites in Europe and Africa and develop a presence in Asia and South America.
Takeda Pharmaceutical has signed an agreement to undertake collaborative research with Keio University School of Medicine (Shinjuku Ward, Tokyo) and Niigata University (Niigata City, Niigata) at Takeda’s Shonan Research Center (Fujisawa City, Kanagawa) regarding the search for and functional analysis of disease-related RNA-binding proteins. This may lead to treatments in CNS and oncology.
Genomics England has announced a new collaboration as part of the 100,000 Genomes Project to accelerate the development of new diagnostics and treatments for patients. Ten pharma and biotech companies have come together to create the Genomics Expert Network for Enterprises (GENE) Consortium to oversee a year-long industry trial.
Takeda Pharmaceutical, a research-based global company headquartered in Osaka, Japan, has licensed exclusive rights to use ImmunoGen‘s ADC technology—including ImmunoGen’s new DNA-acting IGN payload agents—to develop and commercialize targeted anticancer therapeutics to up to two undisclosed targets.